Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
13.62
-1.20 (-8.07%)
At close: Nov 12, 2026, 4:00 PM EST
13.63
+0.01 (0.07%)
Pre-market: Nov 13, 2026, 4:02 AM EST
Trevi Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Trevi Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $28.18. The average 1-year stock price forecast is 106.90% higher than the current stock price, while the lowest is $23 (+68.87%) and the highest is $40 (+193.69%).
Price Target: $28.18 (+106.90%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Trevi Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 9 | 9 | 9 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JonesTrading | JonesTrading | Buy Maintains $28 | Buy | Maintains | $28 | +105.58% | Nov 10, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $23 | Buy | Reiterates | $23 | +68.87% | Nov 10, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Reiterates $25 | Buy | Reiterates | $25 | +83.55% | Nov 10, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +120.26% | Nov 10, 2026 |
| Needham | Needham | Buy Maintains $23 | Buy | Maintains | $23 | +68.87% | Nov 10, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.49
from -0.32
EPS Next Year
-0.59
from -0.49
EPS and Forward PE are based on non-GAAP adjusted numbers.